There is a dosage regimen for amlodipine for use in the treatment of hypertension.

Provided is a method of treatment of COVID-19 and/or preventing infection with SARS-CoV-2 comprising: administering to an individual in need thereof a therapeutically effective dose of mifepristone, or a pharmaceutically acceptable salt and/or analogue thereof, and a therapeutically effective dose of amlodipine, or a pharmaceutically acceptable salt thereof.

Provided is a method of treatment of COVID-19 and/or preventing infection with SARS-CoV-2 comprising: administering to an individual in need thereof a therapeutically effective dose of mifepristone, or a pharmaceutically acceptable salt and/or analogue thereof, and a therapeutically effective dose of amlodipine, or a pharmaceutically acceptable salt thereof.

Provided is a method of treatment of COVID-19 and/or preventing infection with SARS-CoV-2 comprising: administering to an individual in need thereof a therapeutically effective dose of mifepristone, or a pharmaceutically acceptable salt and/or analogue thereof, and a therapeutically effective dose of amlodipine, or a pharmaceutically acceptable salt thereof.

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

The disclosure relates to the field of lymphedema therapy, more specifically, to a new pharmacological strategy to rescue the failed lymph pump system that can supplement, enhance or replace current therapies.

The disclosure relates to the field of lymphedema therapy, more specifically, to a new pharmacological strategy to rescue the failed lymph pump system that can supplement, enhance or replace current therapies.

The present invention relates to a liquisolid pharmaceutical formulation comprising a porous carrier and an active pharmaceutical ingredient loaded onto a surface of the porous carrier, wherein the active pharmaceutical ingredient is dispersed in propylene carbonate or a mixture of propylene carbonate and a further solvent and the dispersion of the active pharmaceutical ingredient and propylene carbonate or a mixture of propylene carbonate and a further solvent is loaded onto the external surface and the internal surface located inside the pores of the porous carrier thereby forming a liquisolid system, and to a process for manufacturing such a liquisolid pharmaceutical formulation.

The present invention relates to a liquisolid pharmaceutical formulation comprising a porous carrier and an active pharmaceutical ingredient loaded onto a surface of the porous carrier, wherein the active pharmaceutical ingredient is dispersed in propylene carbonate or a mixture of propylene carbonate and a further solvent and the dispersion of the active pharmaceutical ingredient and propylene carbonate or a mixture of propylene carbonate and a further solvent is loaded onto the external surface and the internal surface located inside the pores of the porous carrier thereby forming a liquisolid system, and to a process for manufacturing such a liquisolid pharmaceutical formulation.